Tanimoto Tetsuya E, Yamaguchi Takuhiro, Tanaka Yuji, Saito Akiko, Tajima Kinuko, Karasuno Takahiro, Kasai Masanobu, Kishi Kenji, Mori Takehiko, Maseki Nobuo, Morishima Satoko, Miyakoshi Shigesaburo, Kasai Masaharu, Ohno Yuju, Kim Sung-Won, Numata Akihiko, Kami Masahiro, Takaue Yoichi, Mori Shin-ichiro, Harada Mine
First Department of Internal Medicine (Medicine and Biosystemic Science), Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Br J Haematol. 2004 May;125(4):480-93. doi: 10.1111/j.1365-2141.2004.04943.x.
A reduced incidence of graft versus host disease (GvHD) has been documented among Japanese allogeneic bone marrow transplantation (BMT) patients, as the Japanese are genetically more homogeneous than western populations. To clarify whether this ethnic difference affects the results of allogeneic peripheral blood stem cell transplantation (PBSCT), we conducted a nationwide survey to compare clinical outcomes of allogeneic PBSCT (n = 214) and BMT (n = 295) from a human leucocyte antigen-identical-related donor in Japanese patients. The cumulative incidence of grades II-IV acute GvHD was 37.4% for PBSCT and 32.0% for BMT. The cumulative incidence of extensive chronic GvHD at 1 year was significantly higher after PBSCT than BMT (42% vs. 27%; P < 0.01). The organ involvement patterns of GvHD were different between the two groups. By multivariate analyses, the incidence of chronic GvHD was significantly increased in PBSCT, whereas the stem cell source did not affect the incidence of acute GvHD, transplant-related mortality, relapse or survival. We concluded that Japanese PBSCT patients have an increased risk of chronic GvHD compared with BMT patients, but the incidence of acute GvHD was still lower than in western populations. Thus, the choice of haematopoietic stem cell source should be considered based on data for individual ethnic populations.
已有文献记载,在日本异基因骨髓移植(BMT)患者中,移植物抗宿主病(GvHD)的发生率较低,因为日本人在基因上比西方人群更为同质化。为了阐明这种种族差异是否会影响异基因外周血干细胞移植(PBSCT)的结果,我们进行了一项全国性调查,以比较日本患者中来自人类白细胞抗原相同相关供者的异基因PBSCT(n = 214)和BMT(n = 295)的临床结局。II-IV级急性GvHD的累积发生率在PBSCT组为37.4%,在BMT组为32.0%。PBSCT后1年广泛慢性GvHD的累积发生率显著高于BMT(42%对27%;P < 0.01)。两组GvHD的器官受累模式不同。通过多因素分析,PBSCT中慢性GvHD的发生率显著增加,而干细胞来源不影响急性GvHD的发生率、移植相关死亡率、复发率或生存率。我们得出结论,与BMT患者相比,日本PBSCT患者发生慢性GvHD的风险增加,但急性GvHD的发生率仍低于西方人群。因此,应根据各民族人群的数据来考虑造血干细胞来源的选择。